These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 12435171

  • 21. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 22. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC.
    Nefrologia; 2004 Sep; 24(1):54-9. PubMed ID: 15083958
    [Abstract] [Full Text] [Related]

  • 23. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
    Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ.
    Nephrol Dial Transplant; 2004 Apr; 19(4):898-903. PubMed ID: 15031347
    [Abstract] [Full Text] [Related]

  • 24. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A.
    Anticancer Res; 2008 Apr; 28(3B):1767-71. PubMed ID: 18630457
    [Abstract] [Full Text] [Related]

  • 25. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J.
    Best Pract Res Clin Haematol; 2005 Apr; 18(3):407-16. PubMed ID: 15792914
    [Abstract] [Full Text] [Related]

  • 26. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L.
    Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
    Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A.
    Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062
    [Abstract] [Full Text] [Related]

  • 28. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease.
    Suranyi MG, Lindberg JS, Navarro J, Elias C, Brenner RM, Walker R.
    Am J Nephrol; 2003 Jun; 23(2):106-11. PubMed ID: 12481149
    [Abstract] [Full Text] [Related]

  • 29. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
    Agarwal A, Silver MR, Walczyk M, Liu W, Audhya P.
    J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537
    [Abstract] [Full Text] [Related]

  • 30. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
    Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C.
    J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
    [Abstract] [Full Text] [Related]

  • 31. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration.
    Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S.
    Am J Nephrol; 2004 Dec; 24(4):453-60. PubMed ID: 15331889
    [Abstract] [Full Text] [Related]

  • 32. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.
    Canon JL, Vansteenkiste J, Bodoky G, Mateos MV, Bastit L, Ferreira I, Rossi G, Amado RG.
    J Natl Cancer Inst; 2006 Feb 15; 98(4):273-84. PubMed ID: 16478746
    [Abstract] [Full Text] [Related]

  • 33. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, Bridges K.
    Am J Hematol; 2010 Sep 15; 85(9):655-63. PubMed ID: 20661916
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
    Fang YW, Chang CH.
    Perit Dial Int; 2009 Sep 15; 29(2):199-203. PubMed ID: 19293358
    [Abstract] [Full Text] [Related]

  • 36. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
    Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D.
    Oncologist; 2005 Sep 15; 10(8):642-50. PubMed ID: 16177289
    [Abstract] [Full Text] [Related]

  • 37. Clinical trial simulation of a 200-microg fixed dose of darbepoetin alfa in chemotherapy-induced anemia.
    Jumbe N, Yao B, Rovetti R, Rossi G, Heatherington AC.
    Oncology (Williston Park); 2002 Oct 15; 16(10 Suppl 11):37-44. PubMed ID: 12435172
    [Abstract] [Full Text] [Related]

  • 38. [Italian study on the treatment of anaemia in chronic dialysis patients switched over to less frequent doses of darbepoetin from human recombinant erythropoietin (rHuEPO)].
    Del Vecchio L, Villa G, Carraro G, Morosetti M, Pedrini L, Adorati Menegato M, Amato M, Mauro MM, Borgatti P, Malberti F, Marai P, Locatelli F, Gruppo Di Studio NESP 2000 0116 (NESP 3b).
    G Ital Nefrol; 2004 Oct 15; 21(3):259-66. PubMed ID: 15285005
    [Abstract] [Full Text] [Related]

  • 39. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis.
    Macdougall IC, Matcham J, Gray SJ, NESP 960245/246 Study Group.
    Nephrol Dial Transplant; 2003 Mar 15; 18(3):576-81. PubMed ID: 12584282
    [Abstract] [Full Text] [Related]

  • 40. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease.
    Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R.
    Clin Nephrol; 2005 May 15; 63(5):327-34. PubMed ID: 15909591
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.